<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01988649</url>
  </required_header>
  <id_info>
    <org_study_id>STU00086297</org_study_id>
    <nct_id>NCT01988649</nct_id>
  </id_info>
  <brief_title>Oxytocin and Pain Sensitivity and Threshold</brief_title>
  <official_title>The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxytocin is neurohypophysial peptide that acts mainly as a neuromodulator in the brain. In
      addition,oxytocin have an important roles in sexual reproduction , in particular during and
      after childbirth. It facilitates birth, maternal bonding, and, breastfeeding. Nasal oxytocin
      has been commonly used to improve breastfeeding in lactating women. A review of safety , side
      effects and subjective reaction to intranasal oxytocin in human research in 1529 subjects did
      not review any differences from placebo. The vast majority of basic science studies suggested
      a large effect of oxytocin in minimizing acute pain.4 Few studies have demonstrated an
      association between plasma levels of oxytocin and pain in humans. No studies have examined
      the effect of intranasal oxytocin on pain sensitivity and threshold. Since addictive
      properties of oxytocin have not been described, the drug may have important application in
      the management of acute and chronic pain.

      The main objective of the current investigation was to evaluate the effect of intranasal
      oxytocin on pain sensitivity and threshold in human volunteers. We hypothesized that
      intranasal oxytocin, in human volunteers ,would decrease sensitivity and and increase pain
      threshold compared to intranasal saline .

      Significance: Intranasal oxytocin may become a viable treatment for acute and chronic pain in
      humans.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Duplicate Study
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain sensitivity and threshold</measure>
    <time_frame>120 minutes</time_frame>
    <description>Pain sensitivity and threshold using the MEDoc device. Mechanical and thermal pain test will be performed at baseline, before drug administration, at 45 minutes and at 90 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects of Oxytocin</measure>
    <time_frame>2 Hours</time_frame>
    <description>Side effects including running nose, nasal irritation, tears in the eyes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Intranasal Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of 32 units of Oxytocin administered intranasally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of 4 sprays intranasally of normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Oxytocin</intervention_name>
    <description>Administration of intranasal Oxytocin</description>
    <arm_group_label>Intranasal Oxytocin</arm_group_label>
    <other_name>Oxytocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <description>Administration of normal saline intranasally.</description>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females volunteers

          -  English speaking

          -  Age &lt;20 and &gt; 35

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Allergy to preservatives

          -  Mental disease

          -  Chronic pain

          -  Current use of analgesics

          -  Anxiety or depression Drop Out: volunteer request
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Walega, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yamasue H, Yee JR, Hurlemann R, Rilling JK, Chen FS, Meyer-Lindenberg A, Tost H. Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction. J Neurosci. 2012 Oct 10;32(41):14109-17. doi: 10.1523/JNEUROSCI.3327-12.2012. Review.</citation>
    <PMID>23055480</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>David Walega</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Oxytocin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

